![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 20, 17063-17068, May 18, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the DuPont Pharmaceuticals Company, Department of Applied
Biotechnology, Wilmington, Delaware 19880
Integrins are a large family of cell surface
receptors that are involved in a wide range of biological processes.
The integrin
Unusually Stable and Long-lived Ligand-induced Conformations of
Integrins*
IIb
3
(glycoprotein IIb-IIIa) is a major platelet glycoprotein heterodimeric
receptor that mediates platelet aggregation and is currently a target
for pharmaceutical intervention. Ligand binding to the receptor has
been shown to induce conformational changes by physical methods and the
exposure of neoepitopes (the ligand-induced binding sites). Here we
show that the antagonist XP280 induces a conformation that is stable to
treatment with SDS and that the protein retains this conformation for
several days even after dissociation of the inhibitor. These
ligand-induced conformational changes take place with purified protein
and on intact platelets. They are competable with an RGDS peptide and are stable to reduction but not boiling or treatment with EDTA. The
retention of an altered conformation in the absence of the ligand
implies the possibility of ligand-induced alteration of biological
function even in the absence of ligand. Finally, similar behavior is
observed with the integrin
v
3, suggesting
that access to SDS stable conformations may be conserved throughout the
integrin superfamily. The unusual stability, long-lived nature, and
potential generality of these conformations could have profound
implications for integrin biology.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: DuPont Pharmaceutical
Co., Experimental Station, E336/241B, P.O. Box 80336, Wilmington, DE
19880-0336. E-mail: richard.wynn@dupontpharma.com.
This article has been cited by other articles:
![]() |
B.-H. Luo, T. A. Springer, and J. Takagi High Affinity Ligand Binding by Integrins Does Not Involve Head Separation J. Biol. Chem., May 2, 2003; 278(19): 17185 - 17189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Billheimer, I. B. Dicker, R. Wynn, J. D. Bradley, D. A. Cromley, H. E. Godonis, L. C. Grimminger, B. He, C. J. Kieras, D. L. Pedicord, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated Blood, May 15, 2002; 99(10): 3540 - 3546. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Salaun, E. Gyan, P. Rodrigues, and J. M. Heard Pit2 Assemblies at the Cell Surface Are Modulated by Extracellular Inorganic Phosphate Concentration J. Virol., March 27, 2002; 76(9): 4304 - 4311. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |